SOUSA, B PINTO, LF AZEVEDO, SA, A SOUSA, RJ VIEIRA, R AMARAL, L KLIMEK, W CZARLEWSKI, JM ANTO, A BEDBROOK, V KVEDARIENE, MT VENTURA, IJ ANSOTEGUI, KC BERGMANN, L BRUSSINO, GW CANONICA, V CARDONA, CARREIRO, P MARTINS, T CASALE, L CECCHI, T CHIVATO, DK CHU, C CINGI, EM COSTA, AA CRUZ, De Feo G, P DEVILLIER, WJ FOKKENS, M GAGA, B GEMICIOGLU, T HAAHTELA, JC IVANCEVICH, Z ISPAYEVA, M JUTEL, P KUNA, I KAIDASHEV, H KRAXNER, LARENAS, DE LINNEMANN, D LAUNE, B LIPWORTH, R LOUIS, M MAKRIS, R MONTI, MORAIS, M ALMEIDA, R MOSGES, J MULLOL, M ODEMYR, Y OKAMOTO, NG PAPADOPOULOS, V PATELLA, PT NHAN, FS REGATEIRO, S REITSMA, PW ROUADI, B SAMOLINSKI, Milan SOVA, TODO, A BOM, TABORDA, L BARATA, PV TOMAZIC, TOPPILA, S SALMI, J SASTRE, I TSILIGIANNI, A VALIULIS, D WALLACE, S WASERMAN, A YORGANCIOGLU, M ZIDARN, T ZUBERBIER, JA FONSECA, J BOUSQUET a O PFAAR. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. CLINICAL AND TRANSLATIONAL ALLERGY. ENGLAND: WILEY, 2022, roč. 12, č. 3, 13 s. ISSN 2045-7022. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1875237, author = {Sousa, and Pinto, B and Azevedo, LF and Sa, and Sousa, A and Vieira, RJ and Amaral, R and Klimek, L and Czarlewski, W and Anto, JM and Bedbrook, A and Kvedariene, V and Ventura, MT and Ansotegui, IJ and Bergmann, KC and Brussino, L and Canonica, GW and Cardona, V and Carreiro, and Martins, P and Casale, T and Cecchi, L and Chivato, T and Chu, DK and Cingi, C and Costa, EM and Cruz, AA and G, De Feo and Devillier, P and Fokkens, WJ and Gaga, M and Gemicioglu, B and Haahtela, T and Ivancevich, JC and Ispayeva, Z and Jutel, M and Kuna, P and Kaidashev, I and Kraxner, H and Larenas, and Linnemann, DE and Laune, D and Lipworth, B and Louis, R and Makris, M and Monti, R and Morais, and Almeida, M and Mosges, R and Mullol, J and Odemyr, M and Okamoto, Y and Papadopoulos, NG and Patella, V and Nhan, PT and Regateiro, FS and Reitsma, S and Rouadi, PW and Samolinski, B and Sova, Milan and Todo, and Bom, A and Taborda, and Barata, L and Tomazic, PV and Toppila, and Salmi, S and Sastre, J and Tsiligianni, I and Valiulis, A and Wallace, D and Waserman, S and Yorgancioglu, A and Zidarn, M and Zuberbier, T and Fonseca, JA and Bousquet, J and Pfaar, O}, article_location = {ENGLAND}, article_number = {3}, keywords = {allergic rhinitis; immunotherapy; mobile health; patient-reported outcomes; real-life data analysis}, issn = {2045-7022}, journal = {CLINICAL AND TRANSLATIONAL ALLERGY}, note = {Bez afiliace k MU.}, title = {Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model}, url = {https://onlinelibrary.wiley.com/doi/10.1002/clt2.12128}, volume = {12}, year = {2022} }
TY - JOUR ID - 1875237 AU - Sousa, AU - Pinto, B - Azevedo, LF - Sa, AU - Sousa, A - Vieira, RJ - Amaral, R - Klimek, L - Czarlewski, W - Anto, JM - Bedbrook, A - Kvedariene, V - Ventura, MT - Ansotegui, IJ - Bergmann, KC - Brussino, L - Canonica, GW - Cardona, V - Carreiro, AU - Martins, P - Casale, T - Cecchi, L - Chivato, T - Chu, DK - Cingi, C - Costa, EM - Cruz, AA - G, De Feo - Devillier, P - Fokkens, WJ - Gaga, M - Gemicioglu, B - Haahtela, T - Ivancevich, JC - Ispayeva, Z - Jutel, M - Kuna, P - Kaidashev, I - Kraxner, H - Larenas, AU - Linnemann, DE - Laune, D - Lipworth, B - Louis, R - Makris, M - Monti, R - Morais, AU - Almeida, M - Mosges, R - Mullol, J - Odemyr, M - Okamoto, Y - Papadopoulos, NG - Patella, V - Nhan, PT - Regateiro, FS - Reitsma, S - Rouadi, PW - Samolinski, B - Sova, Milan - Todo, AU - Bom, A - Taborda, AU - Barata, L - Tomazic, PV - Toppila, AU - Salmi, S - Sastre, J - Tsiligianni, I - Valiulis, A - Wallace, D - Waserman, S - Yorgancioglu, A - Zidarn, M - Zuberbier, T - Fonseca, JA - Bousquet, J - Pfaar, O PY - 2022 TI - Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model JF - CLINICAL AND TRANSLATIONAL ALLERGY VL - 12 IS - 3 PB - WILEY SN - 20457022 N1 - Bez afiliace k MU. KW - allergic rhinitis KW - immunotherapy KW - mobile health KW - patient-reported outcomes KW - real-life data analysis UR - https://onlinelibrary.wiley.com/doi/10.1002/clt2.12128 N2 - Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air(R) app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK-air(R) data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness. ER -
SOUSA, B PINTO, LF AZEVEDO, SA, A SOUSA, RJ VIEIRA, R AMARAL, L KLIMEK, W CZARLEWSKI, JM ANTO, A BEDBROOK, V KVEDARIENE, MT VENTURA, IJ ANSOTEGUI, KC BERGMANN, L BRUSSINO, GW CANONICA, V CARDONA, CARREIRO, P MARTINS, T CASALE, L CECCHI, T CHIVATO, DK CHU, C CINGI, EM COSTA, AA CRUZ, De Feo G, P DEVILLIER, WJ FOKKENS, M GAGA, B GEMICIOGLU, T HAAHTELA, JC IVANCEVICH, Z ISPAYEVA, M JUTEL, P KUNA, I KAIDASHEV, H KRAXNER, LARENAS, DE LINNEMANN, D LAUNE, B LIPWORTH, R LOUIS, M MAKRIS, R MONTI, MORAIS, M ALMEIDA, R MOSGES, J MULLOL, M ODEMYR, Y OKAMOTO, NG PAPADOPOULOS, V PATELLA, PT NHAN, FS REGATEIRO, S REITSMA, PW ROUADI, B SAMOLINSKI, Milan SOVA, TODO, A BOM, TABORDA, L BARATA, PV TOMAZIC, TOPPILA, S SALMI, J SASTRE, I TSILIGIANNI, A VALIULIS, D WALLACE, S WASERMAN, A YORGANCIOGLU, M ZIDARN, T ZUBERBIER, JA FONSECA, J BOUSQUET a O PFAAR. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. \textit{CLINICAL AND TRANSLATIONAL ALLERGY}. ENGLAND: WILEY, 2022, roč.~12, č.~3, 13 s. ISSN~2045-7022.
|